EDIT Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -101870.49% compared to Editas Medicine's net margin of 11.99%. Editas Medicine's return on equity of -74.59% beat Johnson & Johnson's return on equity of 20.88%.

Editas Medicine has a consensus price target of $8.50, signalling upside risk potential of 173.63%. On the other hand Johnson & Johnson has an analysts' consensus of $174.71 which suggests that it could grow by 20.87%. Given that Editas Medicine has higher upside potential than Johnson & Johnson, analysts believe Editas Medicine is more attractive than Johnson & Johnson.

Editas Medicine has a beta of 1.947, which suggesting that the stock is 94.725% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.514, suggesting its less volatile than the S&P 500 by 48.607%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.41% to investors and pays a quarterly dividend of $1.24 per share. Editas Medicine pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Editas Medicine quarterly revenues are $61K, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Editas Medicine's net income of -$62.1M is lower than Johnson & Johnson's net income of $2.7B. Notably, Editas Medicine's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.78x versus 3.99x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences has a net margin of -101870.49% compared to Editas Medicine's net margin of --. Editas Medicine's return on equity of -74.59% beat Kodiak Sciences's return on equity of --.

Editas Medicine has a consensus price target of $8.50, signalling upside risk potential of 173.63%. On the other hand Kodiak Sciences has an analysts' consensus of $6.67 which suggests that it could fall by -26.9%. Given that Editas Medicine has higher upside potential than Kodiak Sciences, analysts believe Editas Medicine is more attractive than Kodiak Sciences.

Editas Medicine has a beta of 1.947, which suggesting that the stock is 94.725% more volatile than S&P 500. In comparison Kodiak Sciences has a beta of 2.113, suggesting its more volatile than the S&P 500 by 111.317%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Editas Medicine pays -- of its earnings as a dividend. Kodiak Sciences pays out -- of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are larger than Kodiak Sciences quarterly revenues of --. Editas Medicine's net income of -$62.1M is lower than Kodiak Sciences's net income of -$43.9M. Notably, Editas Medicine's price-to-earnings ratio is -- while Kodiak Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.78x versus -- for Kodiak Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -101870.49% compared to Editas Medicine's net margin of 25.23%. Editas Medicine's return on equity of -74.59% beat Pfizer's return on equity of 4.63%.

Editas Medicine has a consensus price target of $8.50, signalling upside risk potential of 173.63%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.83%. Given that Editas Medicine has higher upside potential than Pfizer, analysts believe Editas Medicine is more attractive than Pfizer.

Editas Medicine has a beta of 1.947, which suggesting that the stock is 94.725% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.32% to investors and pays a quarterly dividend of $0.42 per share. Editas Medicine pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Editas Medicine quarterly revenues are $61K, which are smaller than Pfizer quarterly revenues of $17.7B. Editas Medicine's net income of -$62.1M is lower than Pfizer's net income of $4.5B. Notably, Editas Medicine's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.78x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of -101870.49% compared to Editas Medicine's net margin of 13.8%. Editas Medicine's return on equity of -74.59% beat Revvity's return on equity of 3.24%.

Editas Medicine has a consensus price target of $8.50, signalling upside risk potential of 173.63%. On the other hand Revvity has an analysts' consensus of $137.97 which suggests that it could grow by 21.45%. Given that Editas Medicine has higher upside potential than Revvity, analysts believe Editas Medicine is more attractive than Revvity.

Editas Medicine has a beta of 1.947, which suggesting that the stock is 94.725% more volatile than S&P 500. In comparison Revvity has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.677%.

Editas Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.25% to investors and pays a quarterly dividend of $0.07 per share. Editas Medicine pays -- of its earnings as a dividend. Revvity pays out 5.05% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Editas Medicine quarterly revenues are $61K, which are smaller than Revvity quarterly revenues of $684M. Editas Medicine's net income of -$62.1M is lower than Revvity's net income of $94.4M. Notably, Editas Medicine's price-to-earnings ratio is -- while Revvity's PE ratio is 54.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Editas Medicine is 1.78x versus 5.15x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.